FOI 2025/1342

Under the Freedom of Information Act 2000, please provide the following recorded information held by your Integrated Care Board regarding use of bevacizumab gamma (Lytenava®) for neovascular (wet) age-related macular degeneration (NICE TA1022):

Scope & period

1. 1 June 2025 – 30 June 2025
2. 1 July 2025 – 31 July 2025

Information requested (for each month above):

• Total number of Blueteq prior-approval forms submitted for bevacizumab gamma (Lytenava) for wet AMD within your ICB.
• Please split totals into:
  a) Initiation forms (treatment starts)
  b) Continuation forms (ongoing approvals / renewals)
• If held, please also provide a breakdown by provider Trust within your ICB.

Format & identifiers

• Please provide the data in CSV or XLSX.
• Drug identifiers for clarity: bevacizumab gamma (brand: Lytenava®; NICE TA1022; if useful for your systems, PIP code often referenced is 1215680).

Notes

• I am requesting aggregate figures only; no patient-level data are required.
• If your ICB does not hold some or all of this information but your provider Trusts do, please advise and/or transfer this request to the relevant bodies under the FOI Section 45 Code of Practice.
• If any figure is ≤5 and you consider disclosure risky to anonymity, please use standard rounding/redaction (e.g., “≤5”).

If any part of this request risks exceeding the cost limit, please let me know how best to narrow (e.g., omitting the Trust-level split) so that it can be completed within the statutory time.

NHS Greater Manchester currently does not have Blueteq forms in place for bevacizumab gamma (brand: Lytenava®; NICE TA1022).